Título:
Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
Otros títulos:
Coordinador:
Director:
Compilador:
Autor:
Bove, Virginia
Garrido, David
Riva, Eloísa
Garrido, David
Riva, Eloísa
Tutor:
Tipo de documento:
Artículo
Editor:
Palabras clave:
Age
Multiple myeloma
Survival
Transplantation
Multiple myeloma
Survival
Transplantation
Descriptores:
TRASPLANTE DE CÉLULAS
ADULTO JOVEN
MIELOMA MÚLTIPLE
TASA DE SUPERVIVENCIA
ADULTO JOVEN
MIELOMA MÚLTIPLE
TASA DE SUPERVIVENCIA
Año de publicación:
2021
Contenido:
Resumen:
Background: Multiple myeloma is a disease of the elderly. However, 40% of patients are diagnosed before 65 years old. Outcomes regarding age as a prognostic factor in MM are heterogeneous.
Method: We retrospectively analyzed clinical characteristics, response to treatment and survival of 282 patients with active newly-diagnosed multiple myeloma, comparing results between patients younger and older than 65 years.
Main results: The frequency of multiple myeloma in those younger than 66 years was 53.2%. Younger patients presented with a more aggressive disease, more advanced Durie-Salmon stage (85.3% vs 73.5%; p=0.013), extramedullary disease (12.7% vs 0%; p<0.001), osteolytic lesions (78.7% vs 57.6%; p<0.001) and bone plasmacytoma (25.3% vs 11.4%; p=0.003). In spite of this, the overall response rate was similar between groups (80.6% vs 81.4%; p=0.866). The overall survival was significantly longer in young patients (median, 65 months vs 41 months; p=0.001) and higher in those who received autologous hematopoietic stem cell transplantation. The main cause of death was disease progression in both groups. Multivariable analysis revealed that creatinine ≥2mg/dl, extramedullary disease, ≤very good partial remission and non-autologous hematopoietic stem cell transplantation are independent risk factors for shorter survival.
Conclusion: Although multiple myeloma patients younger than 66 years of age have an aggressive presentation, this did not translate into an inferior overall survival, particularly in those undergoing autologous hematopoietic stem cell transplantation.
Descripción:
metadata.articulos.dc.description.uri:
Editorial:
Elsevier
EN:
Hematology, Transfusion and Cell Therapy. 2021;43(3):295-302
Financiadores:
Citación:
Bove V, Garrido D y Riva E. Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma. Hematology Transfusion and Cell Therapy [en línea]. 2021;43(3):295-302
Citación:
metadata.articulos.cc.license.name:
ISBN:
e-ISBN:
ISSN:
ISMN:
Otros identificadores:
Cobertura geográfica:
Cobertura temporal:
Departamento académico:
Grupo de investigación:
Licencia:
Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0)
Colecciones:
| Ficheros | Descripción | Tamaño | Formato | ||
|---|---|---|---|---|---|
| Young age and autologous stem cell transplantation.pdf | Young age and autologous stem cell transplantation | 2.12 MB | Adobe PDF |